Assessing the impact of COVID-19 on liver cancer management (CERO-19)

[Background & Aims] The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

The alpha and ßeta in phase II trials hepatocellular carcinoma ‐ A tale of more than radiological response?